ELIAS JOSEPH JABBOUR to Comorbidity
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Comorbidity.
Connection Strength
0.315
-
Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States. Leuk Lymphoma. 2019 03; 60(3):668-674.
Score: 0.098
-
Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines. Clin Lymphoma Myeloma Leuk. 2015 Dec; 15(12):797-802.
Score: 0.080
-
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014 Sep; 28(5):179-87.
Score: 0.073
-
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. 2019 07 01; 125(13):2233-2241.
Score: 0.025
-
Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep. 2016 Jan; 18(1):4.
Score: 0.020
-
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014 May; 89(5):509-16.
Score: 0.018